Tamsulosin

Sound the Alarm! The Invasion Has Begun in Blizzard Entertainment’s Overwatch® 2

Retrieved on: 
Thursday, August 10, 2023
Entertainment, Consumer Electronics, Technology, General Entertainment, Online, Software, Electronic Games, PvP, Travel, Friends, Tracer, Rotation, Hero, Skin, Xbox Series X and Series S, Xbox One, Mythic, Creativity, Battle.net, Nintendo, Overwatch, Map, Mercy, Sojourn, Flashpoint, Steam, Tamsulosin, Video game, Food delivery, Nightclub, Gasoline, Overwatch 2

There’s something for everyone in Overwatch 2: Invasion, the latest release for Blizzard Entertainment’s cross-platform, team-based action game.

Key Points: 
  • There’s something for everyone in Overwatch 2: Invasion, the latest release for Blizzard Entertainment’s cross-platform, team-based action game.
  • Featuring all-new cinematics and hundreds of new voice lines, players can explore the start of the Overwatch 2 storyline with friends.
  • New Support hero, Illari: The 38th hero to join the game’s roster, Illari is Overwatch’s first Peruvian hero.
  • Drawing her power from the sun, her medium- and long-range abilities allow her to both heal and harm as she sees fit.

Best-Selling Author Sander A. Flaum, Who Coined Benign Paranoia, Pens New Business Book

Retrieved on: 
Tuesday, May 31, 2022
Steps, Pack, Fear, Bristol Myers Squibb, Naproxen, Others, Big Shoes, Sixth, It Happened in Boston?, BP, Marketing, Stutter step, Buddhism, Former, Management, Tamsulosin

), Among Others

Key Points: 
  • ), Among Others
    NEW YORK, May 31, 2022 /PRNewswire/ -- Best-selling author and marketing icon Sander A. Flaum has just released his latest book, Benign Paranoia: The Sixth Sense That Keeps Leaders Ahead of the Pack https://amzn.to/39fgAZZ .
  • After rising to the top in the business world, Sander saw (early in 2022) that there were common traits that successful business people shared.
  • These traits all neatly fell under the umbrella term best described as Benign Paranoia (BP).
  • Author Sander Flaum pens book "Benign Paranoia" with lessons from Tom Von Essen, NYC Fire Commissioner on 9/11.

Prostate Health Markets, 2026: Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 18, 2022
Health, Oncology, CAGR, Patient, Chemotherapy, Man, Inflammation, Cancer vaccine, Pfizer, Prostate, Incidence, Prostate cancer, GlaxoSmithKline, Population, Growth, Tamsulosin, NA, Benign prostatic hyperplasia, BPH, OTC, Merck & Co., C1-inhibitor, USD, Risk, Male, Eli Lilly and Company, Medical imaging, Health insurance, Pharmaceutical industry, Prostatitis

The "Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), & Region (NA, Europe, APAC) - Global Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), & Region (NA, Europe, APAC) - Global Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The three most common forms of prostate disease are inflammation (prostatitis), non-cancerous enlargement of the prostate (benign prostatic hyperplasia or BPH), and prostate cancer.
  • Based on disease indication, the prostate health market is segmented into prostate cancer, benign prostate hyperplasia, and prostatitis.
  • In 2020, prostate cancer accounted for the largest share in the prostate health market.

Benign Prostatic Hyperplasia Treatment Market by Type, End User and Region - Global Forecast to 2026

Retrieved on: 
Monday, March 29, 2021
Medical specialties, Clinical medicine, Chemical compounds, Hair removal, 5α-Reductase inhibitors, Androstanes, Lactams, Teratogens, Benign prostatic hyperplasia, Tamsulosin, Dutasteride, TUMT

DUBLIN, March 29, 2021 /PRNewswire/ -- The "Benign Prostatic Hyperplasia Treatment Market by Type (Drug (Alpha Blockers(Tamsulosin, Doxazosin), 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride), Surgical Treatment (TURP, TUMT, TUNA)), End User (Hospitals) - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 29, 2021 /PRNewswire/ -- The "Benign Prostatic Hyperplasia Treatment Market by Type (Drug (Alpha Blockers(Tamsulosin, Doxazosin), 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride), Surgical Treatment (TURP, TUMT, TUNA)), End User (Hospitals) - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The global benign prostatic hyperplasia treatment market is projected to reach USD 14.1 billion by 2026 from USD 10.8 billion in 2021, at a CAGR of 5.3% from 2021 to 2026.
  • Drug treatment is expected to hold the largest share of the benign prostatic hyperplasia treatment market, by type in 2021.
  • On the basis of region, the benign prostatic hyperplasia treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.

H Code Hires Political Veteran Junelle Cavero Harnal to Deepen Its Political Digital Presence

Retrieved on: 
Monday, June 29, 2020
MEN, Social media, Professional services, Consumer, Other Communications, Other Consumer, Public relations, Investor relations, Marketing, Women, Advertising, Communications, Consulting, Gender-neutral language, Hispanic and Latino, Latinx, Polysemy, Spanish grammar, Morse, Tamsulosin, Linguistics, Language, Terminology

H Code, the only advertising entity reaching the U.S. Latinx market at scale digitally, today announces the hiring of Junelle Cavero Harnal as Political Advisor.

Key Points: 
  • H Code, the only advertising entity reaching the U.S. Latinx market at scale digitally, today announces the hiring of Junelle Cavero Harnal as Political Advisor.
  • We are thrilled to welcome Junelle to our team, said Parker Morse, CEO & Founder of H Code.
  • H Code excels at reaching Latinxs in our country online at scale and more authentically than any other company, adds Cavero Harnal.
  • I look forward to identifying new avenues for H Code and driving further growth and thought leadership in the political landscape.

New Data Show Mirabegron Reduced OAB Symptoms in Men with Benign Prostatic Hyperplasia Currently Treated with Tamsulosin

Retrieved on: 
Sunday, May 5, 2019
RTT, Astellas Pharma, Phenethylamines, Sulfonamides, Tamsulosin, Companies, Placebo, Articles, Medicine, Alpha-1 blocker

PLUS is Astellas' second major trial specifically designed to study the effects of mirabegron in controlling OAB symptoms in men being treated for BPH.

Key Points: 
  • PLUS is Astellas' second major trial specifically designed to study the effects of mirabegron in controlling OAB symptoms in men being treated for BPH.
  • "These results show that mirabegron has the potential to reduce OAB symptoms in men with BPH currently treated with tamsulosin."
  • Overall, 25.9% of patients taking tamsulosin plus mirabegron reported TEAEs vs. 31.4% of tamsulosin plus placebo patients.
  • Drug-related TEAE rates were higher with tamsulosin plus mirabegron patients (11.9%), compared to the tamsulosin plus placebo patients (5.9%).